{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T08:53:22Z","timestamp":1792313602710,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T00:00:00Z","timestamp":1737244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T00:00:00Z","timestamp":1737244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ30847"],"award-info":[{"award-number":["2023JJ30847"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02295-y","type":"journal-article","created":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T07:43:01Z","timestamp":1737272581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease"],"prefix":"10.1186","volume":"30","author":[{"given":"Ronghui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,19]]},"reference":[{"issue":"8","key":"2295_CR1","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/art.42852","volume":"76","author":"X Baraliakos","year":"2024","unstructured":"Baraliakos X, \u00d8stergaard M, Poddubnyy D, van der Heijde D, Deodhar A, Machado PM, et al. Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: results from a head-to-head randomized phase IIIb study. Arthritis Rheumatol. 2024;76(8):1278\u201387. https:\/\/doi.org\/10.1002\/art.42852.","journal-title":"Arthritis Rheumatol"},{"key":"2295_CR2","doi-asserted-by":"publisher","unstructured":"Blair HA. Secukinumab: a review in psoriatic arthritis. Drugs. 2021 Mar; 81(4):483\u2013494. https:\/\/doi.org\/10.1007\/s40265-021-01476-3. Epub 2021 Mar 4. Erratum in: Drugs. 2021; 81(6):735. https:\/\/doi.org\/10.1007\/s40265-021-01513-1.","DOI":"10.1007\/s40265-021-01476-3 10.1007\/s40265-021-01513-1"},{"issue":"2","key":"2295_CR3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/bjd\/ljac040","volume":"188","author":"RG Langley","year":"2023","unstructured":"Langley RG, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren RB, et al. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol. 2023;188(2):198\u2013207. https:\/\/doi.org\/10.1093\/bjd\/ljac040.","journal-title":"Br J Dermatol"},{"issue":"6","key":"2295_CR4","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/jdv.12751","volume":"29","author":"C Paul","year":"2015","unstructured":"Paul C, Lacour JP, Tedremets L, Kreutzer K, Jazayeri S, Adams S, et al. Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082\u201390. https:\/\/doi.org\/10.1111\/jdv.12751.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2295_CR5","doi-asserted-by":"publisher","first-page":"1124628","DOI":"10.3389\/fphar.2023.1124628","volume":"14","author":"Z Deng","year":"2023","unstructured":"Deng Z, Wang S, Wu C, Wang C. IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis. Front Pharmacol. 2023;14:1124628. https:\/\/doi.org\/10.3389\/fphar.2023.1124628.","journal-title":"Front Pharmacol"},{"issue":"11","key":"2295_CR6","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3390\/ph15111365","volume":"15","author":"V Eshwar","year":"2022","unstructured":"Eshwar V, Kamath A, Shastry R, Shenoy AK, Kamath P. A review of the safety of interleukin-17A inhibitor secukinumab. Pharmaceuticals. 2022;15(11):1365. https:\/\/doi.org\/10.3390\/ph15111365.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"2295_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","volume":"21","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111. https:\/\/doi.org\/10.1186\/s13075-019-1882-2.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"2295_CR8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jid.2018.07.029","volume":"139","author":"A Egeberg","year":"2019","unstructured":"Egeberg A, Thyssen JP, Burisch J, Colombel JF. Incidence and risk of inflammatory bowel disease in patients with psoriasis-A nationwide 20-year cohort study. J Invest Dermatol. 2019;139(2):316\u201323. https:\/\/doi.org\/10.1016\/j.jid.2018.07.029.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"2295_CR9","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/bjd.14528","volume":"175","author":"A Egeberg","year":"2016","unstructured":"Egeberg A, Mallbris L, Warren RB, Bachelez H, Gislason GH, Hansen PR, Skov L. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. Br J Dermatol. 2016;175(3):487\u201392. https:\/\/doi.org\/10.1111\/bjd.14528.","journal-title":"Br J Dermatol"},{"issue":"4","key":"2295_CR10","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/ajg.2015.50","volume":"110","author":"FT Moller","year":"2015","unstructured":"Moller FT, Andersen V, Wohlfahrt J, Jess T. Familial risk of inflammatory bowel disease: a population-based cohort study 1977\u20132011. Am J Gastroenterol. 2015;110(4):564\u201371. https:\/\/doi.org\/10.1038\/ajg.2015.50.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2295_CR11","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.gastro.2019.04.016","volume":"157","author":"D Piovani","year":"2019","unstructured":"Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Lytras T, Bonovas S. Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses. Gastroenterology. 2019;157(3):647-659.e4. https:\/\/doi.org\/10.1053\/j.gastro.2019.04.016.","journal-title":"Gastroenterology"},{"issue":"9","key":"2295_CR12","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/ecco-jcc\/jjy063","volume":"12","author":"MJ Fobelo Lozano","year":"2018","unstructured":"Fobelo Lozano MJ, Serrano Gim\u00e9nez R, Castro FM. Emergence of inflammatory bowel disease during treatment with secukinumab. J Crohns Colitis. 2018;12(9):1131\u20133. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy063.","journal-title":"J Crohns Colitis"},{"issue":"5","key":"2295_CR13","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s40257-023-00782-8","volume":"24","author":"M Sticherling","year":"2023","unstructured":"Sticherling M, Nikkels AF, Hamza AM, Kwong P, Szepietowski JC, El Sayed M, Ghislain PD, Khotko AA, Patekar M, Ortmann CE, Forrer P, Papanastasiou P, Keefe D. Secukinumab in pediatric patients with plaque psoriasis: pooled safety analysis from two phase 3 randomized clinical trials. Am J Clin Dermatol. 2023;24(5):821\u201335. https:\/\/doi.org\/10.1007\/s40257-023-00782-8.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"2295_CR14","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1007\/s10620-024-08380-2","volume":"69","author":"S Huynh","year":"2024","unstructured":"Huynh S, Achalu S, Berry R, Lin J, Wang CX, Gubatan J, Cheng AG. Some drugs have two faces: paradoxical colitis in a patient with psoriatic arthritis previously treated with etanercept and IL-17 inhibitors. Dig Dis Sci. 2024;69(5):1602\u20137. https:\/\/doi.org\/10.1007\/s10620-024-08380-2.","journal-title":"Dig Dis Sci"},{"issue":"12","key":"2295_CR15","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693\u2013700. https:\/\/doi.org\/10.1136\/gutjnl-2011-301668.","journal-title":"Gut"},{"issue":"9","key":"2295_CR16","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.cgh.2020.04.069","volume":"19","author":"S Hamdeh","year":"2021","unstructured":"Hamdeh S, Micic D, Hanauer S. Drug-induced colitis. Clin Gastroenterol Hepatol. 2021;19(9):1759\u201379. https:\/\/doi.org\/10.1016\/j.cgh.2020.04.069.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2295_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/1060028016673859","volume":"51","author":"EH Law","year":"2017","unstructured":"Law EH, Badowski M, Hung YT, Weems K, Sanchez A, Lee TA. Association between proton pump inhibitors and microscopic colitis. Ann Pharmacother. 2017;51(3):253\u201363. https:\/\/doi.org\/10.1177\/1060028016673859.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"2295_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41572-021-00273-2","volume":"7","author":"KE Burke","year":"2021","unstructured":"Burke KE, D\u2019Amato M, Ng SC, Pardi DS, Ludvigsson JF, Khalili H. Microscopic colitis. Nat Rev Dis Primers. 2021;7(1):39. https:\/\/doi.org\/10.1038\/s41572-021-00273-2.","journal-title":"Nat Rev Dis Primers"},{"key":"2295_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X19893580","author":"W Haidari","year":"2019","unstructured":"Haidari W, Al-Naqshabandi S, Ahn CS, Bloomfeld RS, Feldman SR. Asymptomatic Crohn\u2019s disease identified in a patient being treated with secukinumab: a case report. SAGE Open Med Case Rep. 2019. https:\/\/doi.org\/10.1177\/2050313X19893580.","journal-title":"SAGE Open Med Case Rep"},{"issue":"13","key":"2295_CR20","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.2169\/internalmedicine.8475-21","volume":"61","author":"K Kakizoe","year":"2022","unstructured":"Kakizoe K, Fujioka S, Noda M, Torisu T. IBD-like lesions in a secukinumab-treated patient. Intern Med. 2022;61(13):2077\u20138. https:\/\/doi.org\/10.2169\/internalmedicine.8475-21.","journal-title":"Intern Med"},{"key":"2295_CR21","doi-asserted-by":"publisher","first-page":"232470962211103","DOI":"10.1177\/23247096221110399","volume":"10","author":"SSK Gandu","year":"2022","unstructured":"Gandu SSK, Khan MH, Vasikaran A, Pandit S. Secukinumab-induced lymphocytic colitis. J Investig Med High Impact Case Rep. 2022;10:23247096221110400. https:\/\/doi.org\/10.1177\/23247096221110399.","journal-title":"J Investig Med High Impact Case Rep"},{"key":"2295_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jdcr.2024.03.017","volume":"48","author":"M Megna","year":"2024","unstructured":"Megna M, De Lucia M, Fornaro L, Tommasino N, Castiglione F, Cacciapuoti S, Testa A. Asymptomatic microscopic colitis induced by secukinumab. JAAD Case Rep. 2024;48:11\u20133. https:\/\/doi.org\/10.1016\/j.jdcr.2024.03.017.","journal-title":"JAAD Case Rep"},{"key":"2295_CR23","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-2-1","author":"KA Fieldhouse","year":"2020","unstructured":"Fieldhouse KA, Ukaibe S, Crowley EL, Khanna R, O\u2019Toole A, Gooderham MJ. Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors. Drugs Context. 2020. https:\/\/doi.org\/10.7573\/dic.2020-2-1.","journal-title":"Drugs Context"},{"issue":"9","key":"2295_CR24","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","volume":"79","author":"M Fauny","year":"2020","unstructured":"Fauny M, Moulin D, D\u2019Amico F, Netter P, Petitpain N, Arnone D, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis. 2020;79(9):1132\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217927.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2295_CR25","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.immuni.2015.10.001","volume":"43","author":"N Whibley","year":"2015","unstructured":"Whibley N, Gaffen SL. Gut-busters: IL-17 ain\u2019t afraid of No IL-23. Immunity. 2015;43(4):620\u20132. https:\/\/doi.org\/10.1016\/j.immuni.2015.10.001.","journal-title":"Immunity"},{"issue":"4","key":"2295_CR26","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","volume":"50","author":"MJ McGeachy","year":"2019","unstructured":"McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity. 2019;50(4):892\u2013906. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.021.","journal-title":"Immunity"},{"issue":"1","key":"2295_CR27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.immuni.2008.11.009","volume":"30","author":"H Ishigame","year":"2009","unstructured":"Ishigame H, Kakuta S, Nagai T, Kadoki M, Nambu A, Komiyama Y, et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity. 2009;30(1):108\u201319. https:\/\/doi.org\/10.1016\/j.immuni.2008.11.009.","journal-title":"Immunity"},{"issue":"28\u201342","key":"2295_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2022.07.005","volume":"69","author":"P Jiang","year":"2023","unstructured":"Jiang P, Zheng C, Xiang Y, Malik S, Su D, Xu G, Zhang M. The involvement of TH17 cells in the pathogenesis of IBD. Cytokine Growth Factor Rev. 2023;69(28\u201342):1. https:\/\/doi.org\/10.1016\/j.cytogfr.2022.07.005.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"2295_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/09546634.2017.1329511","volume":"29","author":"M Hohenberger","year":"2018","unstructured":"Hohenberger M, Cardwell LA, Oussedik E, Feldman SR. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat. 2018;29(1):13\u20138. https:\/\/doi.org\/10.1080\/09546634.2017.1329511.","journal-title":"J Dermatolog Treat"},{"issue":"6025","key":"2295_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1126\/science.1200439","volume":"332","author":"A Puel","year":"2011","unstructured":"Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332(6025):65\u20138. https:\/\/doi.org\/10.1126\/science.1200439.","journal-title":"Science"},{"issue":"5","key":"2295_CR31","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/gutjnl-2012-304154","volume":"62","author":"JF Colombel","year":"2013","unstructured":"Colombel JF, Sendid B, Jouault T, Poulain D. Secukinumab failure in Crohn\u2019s disease: the yeast connection? Gut. 2013;62(5):800\u20131. https:\/\/doi.org\/10.1136\/gutjnl-2012-304154.","journal-title":"Gut"},{"issue":"8","key":"2295_CR32","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.3390\/pharmaceutics15082171","volume":"15","author":"OA Orzan","year":"2023","unstructured":"Orzan OA, \u021aieranu CG, Olteanu AO, Doroban\u021bu AM, Cojocaru A, Mihai MM, et al. An insight on the possible association between inflammatory bowel disease and biologic therapy with IL-17 inhibitors in psoriasis patients. Pharmaceutics. 2023;15(8):2171. https:\/\/doi.org\/10.3390\/pharmaceutics15082171.","journal-title":"Pharmaceutics"},{"key":"2295_CR33","doi-asserted-by":"publisher","first-page":"622934","DOI":"10.3389\/fimmu.2021.622934","volume":"12","author":"H Schmitt","year":"2021","unstructured":"Schmitt H, Neurath MF, Atreya R. Role of the IL23\/IL17 pathway in Crohn\u2019s disease. Front Immunol. 2021;12:622934. https:\/\/doi.org\/10.3389\/fimmu.2021.622934.","journal-title":"Front Immunol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02295-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02295-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02295-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T07:43:03Z","timestamp":1737272583000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02295-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,19]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2295"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02295-y","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,19]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not require an ethical board approval because the study was a retrospective study and did not involve sensitive personal information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}